Biocept Inc. (BIOC)

2.29
NASDAQ : Health Technology
Prev Close 3.03
Day Low/High 2.21 / 2.76
52 Wk Low/High 0.66 / 21.57
Avg Volume 1.35M
Exchange NASDAQ
Shares Outstanding 4.06M
Market Cap 12.30M
EPS -23.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biocept Reports Third Quarter 2018 Financial Results

Biocept Reports Third Quarter 2018 Financial Results

Company to host conference call at 4:30 p.m. Eastern time today

Biocept To Release Third Quarter 2018 Financial Results And Host Investor Conference Call On November 13, 2018

Biocept To Release Third Quarter 2018 Financial Results And Host Investor Conference Call On November 13, 2018

SAN DIEGO , Nov. 6, 2018 /PRNewswire/ -- Biocept, Inc.

Biocept Announces New Executive Hires To Its Sales And Marketing Organization

Biocept Announces New Executive Hires To Its Sales And Marketing Organization

Appoints Scott Nicholson as Vice President of National Sales - US; Cory Dunn as Vice President of Marketing

Biocept To Present At The Dawson James Securities Small Cap Growth Conference On October 30

Biocept To Present At The Dawson James Securities Small Cap Growth Conference On October 30

SAN DIEGO, Oct. 23, 2018 /PRNewswire/ --  Biocept, Inc.

Biocept Obtains Japanese Patent For Its Target Selector Oncogene Mutation Enrichment And Detection Platform

Biocept Obtains Japanese Patent For Its Target Selector Oncogene Mutation Enrichment And Detection Platform

Expands intellectual property to 30 issued patents globally for highly sensitive methods of detecting cancer biomarkers

Biocept To Present At The MicroCap Conference In New York On October 2

Biocept To Present At The MicroCap Conference In New York On October 2

SAN DIEGO, Sept. 25, 2018 /PRNewswire/ --  Biocept, Inc.

Biocept Awarded Patent In Hong Kong For Its Target Selector Platform Using Antibodies And A Microchannel To Perform Liquid Biopsy

Biocept Awarded Patent In Hong Kong For Its Target Selector Platform Using Antibodies And A Microchannel To Perform Liquid Biopsy

Expands the Company's global patent estate for the capture and detection of rare cells of interest, including CTCs shed by solid tumors, in blood and other biofluids

Biocept Announces Pricing Of $2.5 Million Registered Direct Offering Priced At Market

Biocept Announces Pricing Of $2.5 Million Registered Direct Offering Priced At Market

SAN DIEGO, Sept. 21, 2018 /PRNewswire/ -- Biocept, Inc.

Biocept Names Edwin C. Hendrick As Senior Vice President, Chief Commercial Officer

Biocept Names Edwin C. Hendrick As Senior Vice President, Chief Commercial Officer

SAN DIEGO, Sept. 10, 2018 /PRNewswire/ --  Biocept, Inc.

Biocept's Target Selector Platform Featured In Two Poster Presentations At The IASLC 19th World Conference On Lung Cancer

Biocept's Target Selector Platform Featured In Two Poster Presentations At The IASLC 19th World Conference On Lung Cancer

Clinical study data highlight the ability of Biocept's proprietary liquid biopsy technology to detect and monitor actionable biomarkers and circulating tumor cell counts in the blood and in cerebrospinal fluid of non-small cell lung cancer patients

Biocept Reports Second Quarter 2018 Financial Results

Biocept Reports Second Quarter 2018 Financial Results

Company to host conference call at 4:30 p.m. Eastern time today

Biocept To Release Second Quarter 2018 Financial Results And Host Investor Conference Call On August 14, 2018

Biocept To Release Second Quarter 2018 Financial Results And Host Investor Conference Call On August 14, 2018

SAN DIEGO, Aug. 9, 2018 /PRNewswire/ -- Biocept, Inc.

Biocept Announces $11.6 Million In Expected Gross Proceeds From Recently Expired Rights Offering

Biocept Announces $11.6 Million In Expected Gross Proceeds From Recently Expired Rights Offering

SAN DIEGO, Aug. 9, 2018 /PRNewswire/ -- Biocept, Inc.

Biocept Announces Agreement With Managed Care Plan To Study The Benefits Of Implementing Liquid Biopsy To Improve Patient Outcomes And Lower Healthcare Costs

Biocept Announces Agreement With Managed Care Plan To Study The Benefits Of Implementing Liquid Biopsy To Improve Patient Outcomes And Lower Healthcare Costs

Biocept's Target Selector™ to be used in profiling and monitoring patients diagnosed with non-small cell lung cancer throughout an integrated healthcare delivery system

Biocept Awarded Patent In Canada For Its Target Selector CTC Platform

Biocept Awarded Patent In Canada For Its Target Selector CTC Platform

Further expands global patent estate for capturing and detecting biological targets of interest including rare cells such as circulating tumor cells (CTCs)

European Patent Granted For Biocept's Target Selector Oncogene Mutation Enrichment And Detection Platform

European Patent Granted For Biocept's Target Selector Oncogene Mutation Enrichment And Detection Platform

Expands intellectual property to 27 issued patents globally for highly sensitive methods of detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs)

These 5 Stocks Under $10 Could Explode Up Soon

These 5 Stocks Under $10 Could Explode Up Soon

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

Insider Trading Alert - BA, WLL And BIOC Traded By Insiders

Insider Trading Alert - BA, WLL And BIOC Traded By Insiders

Stocks with insider trader activity include BA, WLL and BIOC

8 Stocks Under $10 to Trade for Big Gains

8 Stocks Under $10 to Trade for Big Gains

These under-$10 stocks are making big moves higher. Here's how to trade them from here.

Biocept (BIOC) Stock Popping on Blue Cross Blue Shield Partnership

Biocept (BIOC) Stock Popping on Blue Cross Blue Shield Partnership

Biocept (BIOC) stock is surging in mid-morning trading on Tuesday after the company announced an agreement with Blue Cross Blue Shield of Illinois.

Rosetta Genomics And Biocept Advance Collaboration To Proof-of-Concept Studies Aimed At MicroRNA Profiling Of Circulating Tumor Cells To Enhance Lung Cancer Diagnosis

Rosetta Genomics And Biocept Advance Collaboration To Proof-of-Concept Studies Aimed At MicroRNA Profiling Of Circulating Tumor Cells To Enhance Lung Cancer Diagnosis

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, and Biocept, Inc.

Lung Cancer Study Demonstrates Extremely High Sensitivity Of Biocept's Blood-Based Liquid Biopsy Platform In Detecting EGFR Mutation In Plasma With 93% Concordance With Tissue Biopsy

Lung Cancer Study Demonstrates Extremely High Sensitivity Of Biocept's Blood-Based Liquid Biopsy Platform In Detecting EGFR Mutation In Plasma With 93% Concordance With Tissue Biopsy

Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of cancer, today announced that findings...

Biocept To Present At 2015 Aegis Growth Conference

Biocept To Present At 2015 Aegis Growth Conference

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael Nall is scheduled to...

Biocept Announces Participation In MultiPlan's Networks

Biocept Announces Participation In MultiPlan's Networks

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that it has entered into an agreement with MultiPlan,...

Biocept Secures Agreements With Preferred Provider Organizations Stratose And Galaxy Health Network For Its Proprietary Blood-Based Oncology Diagnostic Assays

Biocept Secures Agreements With Preferred Provider Organizations Stratose And Galaxy Health Network For Its Proprietary Blood-Based Oncology Diagnostic Assays

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing assays for liquid biopsies to improve the detection and treatment of cancer, announces additional agreements with preferred...

Biocept Expands U.S. Microchannel Patent Protection

Biocept Expands U.S. Microchannel Patent Protection

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces the allowance of U.

Biocept's Liquid Biopsy Lung Cancer Target Selector Assay To Be Featured At World Conference On Lung Cancer

Biocept's Liquid Biopsy Lung Cancer Target Selector Assay To Be Featured At World Conference On Lung Cancer

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that clinical data from a study conducted with...

TheStreet Quant Rating: E+ (Sell)